Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000935108 | SCV001080849 | likely benign | Rhabdoid tumor predisposition syndrome 2 | 2023-12-05 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002258056 | SCV002532922 | likely benign | Hereditary cancer-predisposing syndrome | 2021-02-02 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV002258056 | SCV002625856 | likely benign | Hereditary cancer-predisposing syndrome | 2015-12-21 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV003478588 | SCV004220434 | uncertain significance | not provided | 2023-05-11 | criteria provided, single submitter | clinical testing | To the best of our knowledge, this variant has not been reported in the published literature. It also has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). Analysis of this variant using software algorithms for the prediction of the effect of nucleotide changes on splicing yielded predictions that this variant does not affect SMARCA4 mRNA splicing . Based on the available information, we are unable to determine the clinical significance of this variant. |